These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26176402)

  • 1. Delamanid for Extensively Drug-Resistant Tuberculosis.
    Gupta R; Geiter LJ; Wells CD; Gao M; Cirule A; Xiao H
    N Engl J Med; 2015 Jul; 373(3):291-2. PubMed ID: 26176402
    [No Abstract]   [Full Text] [Related]  

  • 2. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Kuksa L; Barkane L; Hittel N; Gupta R
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122917
    [No Abstract]   [Full Text] [Related]  

  • 3. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
    Sotgiu G; Pontali E; Centis R; D'Ambrosio L; Migliori GB
    Expert Rev Anti Infect Ther; 2015 Mar; 13(3):305-15. PubMed ID: 25645397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
    N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing is everything for compassionate use of delamanid.
    Barry CE
    Nat Med; 2015 Mar; 21(3):211. PubMed ID: 25742452
    [No Abstract]   [Full Text] [Related]  

  • 8. Bedaquiline plus delamanid for XDR tuberculosis.
    Lachâtre M; Rioux C; Le Dû D; Fréchet-Jachym M; Veziris N; Bouvet E; Yazdanpanah Y
    Lancet Infect Dis; 2016 Mar; 16(3):294. PubMed ID: 26973310
    [No Abstract]   [Full Text] [Related]  

  • 9. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

  • 10. Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.
    Lardizabal AA; Khan AN; Bamrah Morris S; Goswami ND
    MMWR Morb Mortal Wkly Rep; 2018 Sep; 67(35):996-997. PubMed ID: 30188880
    [No Abstract]   [Full Text] [Related]  

  • 11. Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
    Shah I; Gandhi S; Shetty NS
    Pediatr Infect Dis J; 2020 Jun; 39(6):512-513. PubMed ID: 32032176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access sought to tuberculosis drug from nutraceutical company.
    Gruber K
    Nat Med; 2015 Feb; 21(2):103. PubMed ID: 25642939
    [No Abstract]   [Full Text] [Related]  

  • 13. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
    Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.
    Diacon AH; Dawson R; Hanekom M; Narunsky K; Venter A; Hittel N; Geiter LJ; Wells CD; Paccaly AJ; Donald PR
    Int J Tuberc Lung Dis; 2011 Jul; 15(7):949-54. PubMed ID: 21682970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD; Lynch JB
    Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
    Skripconoka V; Danilovits M; Pehme L; Tomson T; Skenders G; Kummik T; Cirule A; Leimane V; Kurve A; Levina K; Geiter LJ; Manissero D; Wells CD
    Eur Respir J; 2013 Jun; 41(6):1393-400. PubMed ID: 23018916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Easier cure for resistant TB.
    Cohen J
    Science; 2017 Feb; 355(6326):677. PubMed ID: 28209851
    [No Abstract]   [Full Text] [Related]  

  • 18. Compassionate and optimum use of new tuberculosis drugs.
    Matteelli A; D'Ambrosio L; Centis R; Tadolini M; Migliori GB
    Lancet Infect Dis; 2015 Oct; 15(10):1131-1132. PubMed ID: 26461941
    [No Abstract]   [Full Text] [Related]  

  • 19. Compassionate and optimum use of new tuberculosis drugs.
    Reed C; Mason L; Cox H; Seaworth B; Lessem E; Furin J
    Lancet Infect Dis; 2015 Oct; 15(10):1131. PubMed ID: 26461942
    [No Abstract]   [Full Text] [Related]  

  • 20. Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
    Master I; Furin J
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):985-7. PubMed ID: 27287655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.